Guido Marcucci

Oct 2, 2024 | nature.com | Chinmayee Goda |Ozlen Balcioglu |Lalit Sehgal |Bin Zhang |Guido Marcucci |Elaine R. Mardis | +4 more

AbstractLeukemias arise from recurrent clonal mutations in hematopoietic stem/progenitor cells (HSPCs) that cause profound changes in the bone marrow microenvironment (BMM) favoring leukemic stem cell (LSC) growth over normal HSPCs. Understanding the cross talk between preleukemic mutated HSPCs and the BMM is critical to develop novel therapeutic strategies to prevent leukemogenesis. We hypothesize that preleukemic-LSCs (pLSCs) induce BMM changes critical for leukemogenesis.

May 16, 2024 | onlinelibrary.wiley.com | Rebecca Bystrom |Jan Philipp Bewersdorf |Shai Shimony |Rory M. Shallis |Yiwen Liu |guillaume BERTON | +9 more

To the Editor: Intensive induction chemotherapy followed by consolidation therapy with additional chemotherapy and/or an allogeneic hematopoietic stem cell transplant (allo-SCT) is the standard of care for younger and fit patients with acute myeloid leukemia (AML).1 For older AML patients or those deemed unfit for intensive chemotherapy, the addition of the BCL2 inhibitor venetoclax to hypomethylating agents (HMA + VEN) has been shown to improve overall survival (OS) compared with HMA...

Apr 20, 2024 | nature.com | Jiamin Guo |Li Du |Rui Su |Zhenhua Chen |Guido Marcucci |Lili Wang | +3 more

AbstractTargeting the metabolic dependencies of acute myeloid leukemia (AML) cells is a promising therapeutical strategy. In particular, the cysteine and methionine metabolism pathway (C/M) is significantly altered in AML cells compared to healthy blood cells. Moreover, methionine has been identified as one of the dominant amino acid dependencies of AML cells.

Feb 20, 2024 | nature.com | Shai Shimony |Jan Philipp Bewersdorf |Rory M. Shallis |Guido Marcucci |Daniel DeAngelo |Donna S. Neuberg | +1 more

AbstractMolecularly defined secondary acute myeloid leukemia is associated with a prior myeloid neoplasm and confers a worse prognosis. We compared outcomes of molecularly defined secondary AML patients (n = 395) treated with daunorubicin and cytarabine (7 + 3, n = 167), liposomal daunorubicin and cytarabine (CPX-351, n = 66) or hypomethylating agents (HMA) + venetoclax (VEN) (n = 162). Median overall survival (OS) was comparable between treatment groups among patients aged >60 years.

Jan 23, 2024 | nature.com | Jacob Appelbaum |Ing S. Tiong |Stephen B. Ting |Richard Stone |Guillermo Garcia-Manero |Guido Marcucci | +4 more

This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access 251,40 € per year only 20,95 € per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout Data availability For original, de-identified data and/or computer code (R) for analyses please contact the corresponding author ([email protected])....